China-United States Research Collaborations in Antimicrobial Resistance

• Published in: Clinical infectious diseases Vol. 67; no. suppl_2; pp. S142 - S145
• Main Authors: van Duin, David, Gu, Peidi, Dong, Jane, Paff, Melanie, Arias, Rebekka M, Evans, Beth, Yu, Yunsong, Li, Lanjuan, Zhang, Fujie, Liu, Zhengyin, Cao, Bin, Fowler, Vance G, Wang, Minggui
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 13.11.2018
• Subjects: Anti-Bacterial Agents - adverse effects; Biomedical Research - trends; China; Clinical Trials as Topic; Delivery of Health Care; Drug Resistance, Multiple, Bacterial; Humans; Internationality; Observational Studies as Topic; Public-Private Sector Partnerships; Supplement; United States; United States; China; ARLG; clinical trials; antibacterial resistance; United States; China
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1093/cid/ciy694

Abstract A strong synergy can result from China-US antimicrobial resistance (AMR) collaborations given similarities and differences between their respective healthcare systems and research infrastructures. The Antibacterial Resistance Leadership Group has employed a model of realistic growth, starting with a feasible, relatively low-resource observational study in a critical priority pathogen. This and other observational studies will provide vital scientific information required for the rational design of future interventional trials. In addition, it provides a mutual, low-risk opportunity for determining the strengths and opportunities of the research collaboration. Issues identified during the observational studies can be addressed prior to the initiation of high-resource interventional studies. Collaborative clinical AMR studies between China and the United States have tremendous potential to decrease AMR rates, improve responsible antibiotic use, and ultimately improve the lives of patients in both countries.